Keyphrases
Allopurinol
96%
Inflammatory Bowel Disease
96%
Thiopurines
56%
Anti-tumor Necrosis Factor (anti-TNF)
53%
Ulcerative Colitis
53%
Crohn's Disease
53%
Remission
51%
Monotherapy
48%
Randomized Controlled Trial
48%
Investigator-initiated
48%
Thiopurine Therapy
48%
Clinical Care
48%
Clinical Research
48%
Online Registry
48%
Clinical Assessment
48%
Concomitant Treatment
48%
Confidence Interval
29%
Infliximab
24%
Disease Duration
19%
Fecal Calprotectin
19%
Severe Ulcerative Colitis
16%
Moderate to Severe
16%
Denmark
16%
One Dose
16%
Incidence Rate
16%
Clinical Remission
13%
Calendar Period
10%
Relapse Risk
9%
Meta-analysis
9%
Hemoglobin
9%
Biochemical Relapse
9%
Anti-tumor Necrosis Factor Therapy
9%
Calprotectin
9%
Relapse Rate
9%
First Year
9%
Harvey-Bradshaw Index
9%
Red Blood Cells
9%
6-Thioguanine (6-TG)
9%
Odds Ratio
8%
Remission Rate
8%
Unblinding
8%
User Level
8%
Combination Therapy
8%
First-line Therapy
8%
Beneficial Effects
8%
Nave
8%
Once-daily
8%
Capital Region
8%
Adult Patients
8%
Adverse Events
8%
Pharmacology, Toxicology and Pharmaceutical Science
Mercaptopurine
100%
Allopurinol
96%
Ulcerative Colitis
53%
Crohn's Disease
53%
Remission
51%
Tumor Necrosis
48%
Randomized Controlled Trial
48%
Monotherapy
48%
Inflammatory Bowel Disease
48%
Azathioprine
48%
Cohort Study
48%
Calgranulin
24%
Disease Duration
16%
Infliximab
11%
Tioguanine
8%
Observational Study
8%
Recurrence Risk
8%
Tumor Necrosis Factor
5%
